Psilocybin ruling by FDA 10/27/18
The US Food and Drug Administration has given a group of psychiatrists its blessing to dose patients with magic mushrooms in therapy sessions. This week, the FDA granted “Breakthrough Therapy” designation to COMPASS Pathways’ psilocybin-assisted therapy for treatment-resistant depression. The London-based life sciences company, backed in part by Peter Thiel, will use the psychedelic drug psilocybin, the active chemical extracted from psychedelic mushrooms, to treat patients in Europe and North America in a Phase 2b trial to determine the optimal dose of the drug.
Leave a Reply